A bio-pharmaceutical research consortium enforces the following regulatory guidelines for all clinical trials:
1. Every international multi-site trial conducted by the consortium requires central Ethics Board approval prior to the initiation of patient enrollment.
2. Any trial receiving central Ethics Board approval that includes pediatric participants must undergo an independent pediatric safety review.
During a recent compliance audit, investigators noted that Trial X was conducted as an international multi-site trial and enrolled pediatric participants, but never underwent an independent pediatric safety review.
Evaluate the validity of the following statement based on the information above: "Patient enrollment for Trial X was initiated without prior approval from the central Ethics Board."
Cevap: Cevap